NCT02112903View on ClinicalTrials.gov

Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2014

Conditions
Healthy Women
Interventions
DRUG

Encapsulated vortioxetine IR tablet, 20 mg

DRUG

Vortioxetine MR capsule 20 mg (pH 5.5)

DRUG

Vortioxetine MR capsule 20 mg (pH 6.0)

DRUG

Vortioxetine MR capsule 20 mg (pH 7.0)

Trial Locations (1)

NW10 7EW

GB801, London

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT02112903 - Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women | Biotech Hunter | Biotech Hunter